Insulin Aspart Sanofi (Insulin Aspart)

Insulin Aspart binds to insulin receptors on muscle, fat, and liver cells, activating intracellular signaling pathways that increase glucose uptake, inhibit hepatic glucose production, and promote glycogen synthesis, thereby lowering circulating blood glucose levels.

The dose of Insulin Aspart is individualized. A qualified prescriber determines the total daily dose, the timing relative to meals, and any dose adjustments based on the patient’s blood‑glucose monitoring, dietary intake, and overall treatment plan.

Safety data for Insulin Aspart during pregnancy and lactation are limited. Use should be considered only if the potential benefit justifies the potential risk, and decisions must be made in consultation with a qualified healthcare professional.

To order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain logistics), and required import documentation.

Insulin Aspart has a rapid onset of action similar to other rapid‑acting analogs such as insulin lispro and insulin glulisine. Compared with regular human insulin, it reaches peak activity faster and has a shorter duration, offering greater flexibility around meal timing.

Insulin Aspart must be stored in a refrigerator at 2‑8 °C, protected from light. Do not freeze or shake the vial. Once in use, it may be kept at controlled room temperature (up to 30 °C) for a limited period, as indicated on the label.

Insulin Aspart is administered by subcutaneous injection, typically into the abdomen, thigh, or upper arm. It is usually injected within 5‑10 minutes before a meal to match the rise in post‑prandial glucose.

The most serious risks include severe hypoglycemia, which can cause seizures, loss of consciousness, or coma, and allergic reactions ranging from rash to anaphylaxis. Prompt medical attention is required if any of these events occur.

Insulin Aspart is contraindicated in individuals with a known hypersensitivity to insulin Aspart or any of the formulation’s excipients. Patients with severe hypoglycemia unawareness or those unable to monitor glucose levels should also avoid use until appropriate supervision is arranged.